New data: The 340B program is driving up costs for patients and our health care system

Guess what? The 340B program grew, yet again, hitting a whopping$43.9 billion in sales at the discounted 340B price in 2021. But there has not been evidence of corresponding growthin care provided to vulnerable patients at340B covered entities. And making matters worse, fresh data show that 340B may actually be driving up costs for some patients and our health care system as whole. The program of today is having the opposite effect of what Congress intended when they created 340B. That ’s a problem.
Source: The Catalyst - Category: Pharmaceuticals Tags: 340B Source Type: news